NEW YORK, July 7, 2026, 12:03 EDT
- Pfizer Inc. NYSE:PFE was up 1.7% to $24.13 late Tuesday morning. Shares dropped 2.47% on Monday.
- HSBC downgraded Pfizer to Hold from Buy and dropped its price target to $28 from $32.
- The $4 per-share target drop amounts to around $22.9 billion using Pfizer’s diluted share count. That’s more than two years’ worth of annual dividend payouts at the current rate.
- Investors have to wait for evidence in cancer and obesity as the yield stays close to 7%.
Pfizer Inc. NYSE:PFE traded up 1.7% at $24.13 as of 11:48 a.m. EDT Tuesday, recovering some ground after Monday’s 2.47% slide to $23.72. The stock’s loss on Monday stood out with the S&P 500 up 0.72% and the Dow up 0.29%, making it a clear underperformer, not just a victim of the broader market.
HSBC moved Pfizer to Hold from Buy and slashed its price target to $28 from $32, pointing to less confidence in a near-term re-rating. The firm now gives a 40% probability to market for sigvotatug vedotin, down after a Phase 3 lung cancer miss, and bumped its beta assumption to 0.85, up from 0.78.
The main focus now is the scale of the reset, not the rating change. Based on 5.73 billion Pfizer shares, the $4 drop in HSBC’s target slices roughly $22.9 billion from the value HSBC was implying. Pfizer’s quarterly dividend of $0.43 comes out to $1.72 each year, adding up to about $9.9 billion of cash with that same share count. The yield was sitting at about 7.1% as of Tuesday’s price.
| Pfizer market math | Latest figure | Investor read |
|---|---|---|
| HSBC old target | $32 | Earlier upside scenario |
| HSBC new target | $28 | Remains roughly 16% over Tuesday’s closing price |
| Target cut | $4 a share | Target down by about 12.5% |
| Implied target-value cut | About $22.9 billion | That’s around 2.3 years’ worth of the annual payout |
| Annualized dividend | $1.72 a share | Yield now around 7.1% at $24.13 |
| Monday fall recovered Tuesday | About 68% | Stock reversed a chunk, but hasn’t made it all back after the downgrade |
Pfizer lagged other big healthcare names Monday. Shares dropped more than Johnson & Johnson NYSE:JNJ and Eli Lilly NYSE:LLY. Abbott Laboratories NYSE:ABT gained.
| Company | Monday move | Monday close |
|---|---|---|
| Pfizer NYSE:PFE | fell 2.47% | $23.72 |
| Johnson & Johnson NYSE:JNJ | dropped 1.41% | $259.33 |
| Eli Lilly NYSE:LLY | lost 1.14% | $1,200.06 |
| Abbott Laboratories NYSE:ABT | rose 0.24% | $95.63 |
HSBC analysts Rajesh Kumar and Dylan Whitfield said the old Pfizer bull case leaned on ramped-up R&D, a nearly 6% dividend yield, and management aiming for high single-digit revenue gains from 2028 to 2032. Now, they point to more solid signs for sigvotatug vedotin, atirmociclib, the VEGF-bispecific oncology line, and obesity drugs hitting around 2027. They also mention growing headwinds from most-favored-nation drug pricing, IRA impacts, and looming loss-of-exclusivity.
Oncology is taking the biggest short-term blow. Pfizer said June 22 that its sigvotatug vedotin missed the main survival goal versus docetaxel in its SigVie-002 Phase 3 study in previously treated metastatic non-squamous non-small cell lung cancer, which enrolled 703 patients. Pfizer reported that patients with only one prior line of therapy, making up about two-thirds of the trial, saw better trends for survival and progression-free survival.
Jeff Legos, who heads oncology at Pfizer, called this patient group “historically difficult-to-treat.” Solange Peters, chair of medical oncology and the thoracic cancers clinic at Lausanne University Hospital, said docetaxel shouldn’t be underestimated as “a comparator in this setting.” Pfizer
The asset is key since Pfizer paid around $43 billion for Seagen in 2023, aiming to beef up its cancer drug lineup. The deal pushed Pfizer’s oncology pipeline to 60 programs. CEO Albert Bourla said then the firm was “going all in on cancer.” Pfizer
Leadership changes also factor into the discount. Pfizer said June 18 that CFO Dave Denton will leave Aug. 15. Cecile Guegan will take over as interim CFO while the firm looks for a new finance chief. CEO Bourla called Denton a “trusted steward.” But Scotiabank’s Louise Chen told Reuters Denton’s exit puts fresh questions on Pfizer’s 2026 outlook, succession, and timing just as it shifts into obesity drugs. Pfizer
There are offsets, but these won’t resolve the growth story in the near term. On June 24, the FDA gave the nod to Pfizer’s Ibrance in combination with trastuzumab, with or without pertuzumab, plus endocrine therapy for maintenance in HR-positive, HER2-positive locally advanced or metastatic breast cancer after induction. According to the FDA, PATINA saw a statistically significant boost in progression-free survival, with a hazard ratio of 0.76.
Pfizer in May projected 2026 revenue between $59.5 billion and $62.5 billion, and put its adjusted diluted EPS range at $2.80 to $3.00. The company said that outlook excludes share buybacks in 2026, with management saying dividend support and progress with the pipeline remain the equity focus.
Related articles: NYSE:PFE
